Alzheimer disease neuropathology: understanding autonomic dysfunction

Eliasz Engelhardt1, Jerson Laks2

Abstract – Alzheimer’s disease is a widely studied disorder with research focusing on cognitive and functional impairments, behavioral and psychological symptoms, and on abnormal motor manifestations. Despite the importance of autonomic dysfunctions they have received less attention in systematic studies. The underlying neurodegenerative process of AD, mainly affecting cortical areas, has been studied for more than one century. However, autonomic-related structures have not been studied neuropathologically with the same intensity. The autonomic nervous system governs normal visceral functions, and its activity is expressed in relation to homeostatic needs of the organism’s current physical and mental activities. The disease process leads to autonomic dysfunction or dysautonomy possibly linked to increased rates of morbidity and mortality. Objective: The aim of this review was to analyze the cortical, subcortical, and more caudal autonomic-related regions, and the specific neurodegenerative process in Alzheimer’s disease that affects these structures. Methods: A search for papers addressing autonomic related-structures affected by Alzheimer’s degeneration, and under normal condition was performed through MedLine, PsycInfo and Lilacs, on the bibliographical references of papers of interest, together with a manual search for classic studies in older journals and books, spanning over a century of publications. Results: The main central autonomic-related structures are described, including cortical areas, subcortical structures (amygdala, thalamus, hypothalamus, brainstem, cerebellum) and spinal cord. They constitute autonomic neural networks that underpin vital functions. These same structures, affected by specific Alzheimer’s disease neurodegeneration, were also described in detail. The autonomic-related structures present variable neurodegenerative changes that develop progressively according to the degenerative stages described by Braak and Braak. Conclusion: The neural networks constituted by the central autonomic-related structures, when damaged by progressive neurodegeneration, represent the neuropathological substrate of autonomic dysfunction. The presence of this dysfunction and its possible relationship with higher rates of morbidity, and perhaps of mortality, in affected subjects must be kept in mind when managing Alzheimer’s patients.

Key words: Alzheimer, neurodegeneration, autonomic, autonomic dysfunction, dysautonomy.

A neuropatologia da doença de Alzheimer: entendendo a disfunção autônoma

Resumo – A doença da Alzheimer é uma doença amplamente estudada com foco nos comprometimentos cognitivo e funcional, sintomas de comportamento e psicológicos e manifestações motoras anormais. As disfunções autônomas, apesar de sua importância, foram menos consideradas por estudos sistemáticos. O processo neurodegenerativo subjacente dessa doença, principalmente nas áreas corticais, vem sendo estudado há mais de um século. Entretanto, estruturas autônomas não foram estudadas do ponto de vista neuropatológico com o mesmo interesse. O sistema nervoso autônomo encontra-se relacionado a funções viscerais normais e sua atividade é expressa em relação a necessidades homeostáticas das atividades correntes físicas e mentais do organismo. O processo da doença leva a disfunção autônoma ou disautonomia, possivelmente relacionada com taxas maiores de morbidade e mortalidade. Objetivo: O foco dessa revisão é analisar as estruturas autônomas corticais, subcorticais e mais caudais, assim como o processo neurodegenerativo específico da doença de Alzheimer que acomete essas estruturas. Métodos: Foi realizada busca de artigos sobre estruturas autônomas atingidas pela degeneração de Alzheimer e em condições de normalidade, através do MedLine, PsycInfo e Lilacs, assim como nas referências bibliográficas dos artigos de interesse encontrados, busca manual de estudos clássico em periódicos e livros mais antigos, abrangendo mais de um século de publicações. Resultados: As principais estruturas autônomas

1MD, PhD, Coordinator of the Cognitive and Behavioral Unit – INDC-UFRJ. 2MD, PhD, Coordinator of the Alzheimer’s Disease Unit – CDA/IPUB-UFRJ.

Eliasz Engelhardt – Rua Barata Ribeiro, 370/504 - 22040-000 Rio de Janeiro RJ - Brasil. E-mail: eliasz@centroin.com.br

Received July 14, 2008. Accepted in final form August 22, 2008.
The autonomic nervous system (ANS) is responsible for the coordinated control of several visceral systems, such as the cardiovascular, respiratory, and digestive systems. Under normal conditions, this function is adjusted aiming at homeostasis as a response to physical efforts. It is also adjusted in relation to changing mental activities. In this sense, it can be said that in a normal organism, somatic and mental (emotional, cognitive) activities are always accompanied by adjustments in ANS control. The regulation of control enables these complex activities to meet their basic needs. The two extreme paradigms of mobilization of the ANS are represented by the “quiet-rest” and “fight-and-flight” states. A broad spectrum of intermediary possibilities which occur in daily life lay between these two states, both during wakefulness and during the several stages of sleep. The mobilization of the ANS is always graded according to the current needs of the situation.\(^1\)\(^-\)\(^10\)

Damage to the ANS that impairs function beyond compensatory limits may yield dysfunctional states in several organs and systems, representing a picture of “autonomic dysfunction” or “dysautonomia.” These disorders may manifest themselves as autonomic hyperactivity (e.g., hypertension, arrhythmias, hyperhidrosis), or as autonomic failure (e.g., orthostatic hypotension, gastrointestinal tract hypomotility, incontinence). Some of these manifestations may be asymptomatic and detectable only on clinical examination or autonomic testing. Others may be life threatening, such as ventricular arrhythmias, or can cause severe impairment in daily activities, such as orthostatic hypotension. In general, autonomic hyperactivity tends to occur in the context of acute neurologic disease (e.g., cerebrovascular ictus), whereas neurodegenerative disorders (e.g., the well-studied Parkinson’s disease and Dementia with Lewy Bodies, and the less studied Alzheimer’s disease) are commonly associated with autonomic failure. Autonomic responses to cognitive challenge and emotionally significant stimuli may also be impaired, indicating a defective linkage between mental status and autonomic responses, which is important in the pathogenesis of autonomic dysfunction. It is possible that autonomic dysfunction in Alzheimer’s disease is related to the higher rates of morbidity (due to cardiovascular, respiratory, gastrointestinal, bladder disorders) and mortality observed among the affected patients.\(^5\)\(^-\)\(^14\)

The objective of the present review was twofold. First, the general constituents and integrative aspects of the central autonomic nervous system were discussed, followed by a description of the main autonomic-related structures and their interconnections under normal conditions. Second, a systematic description of the same autonomic-related structures affected by Alzheimer’s neurodegenerative pathology was provided. Lastly, some considerations were presented to understand the damaged structures from a functional viewpoint in the context of derranged autonomic neural networks, as well as the clinical repercussions in the light of the autonomic dysfunction.

**Methods**

A broad search spanning over one century was performed for papers investigating autonomic-related structures affected by Alzheimer’s neuropathology, and the same structures studied from normal anatomical and functional viewpoints. Sources included MedLine, PsycInfo and Lilacs, as well as the bibliographical references of the papers of interest. In a further effort to locate relevant information, a manual search for classical studies in older journals and books was also performed. This search included papers written in several languages (English, German, French, Spanish and Portuguese).

**The autonomic nervous system**

The ANS comprises central and peripheral structures. The central structures are constituted by three components that integrate complex autonomic functional patterns, and associate cognitive and behavioral manifestations with autonomic expression (i) nuclei that contain preganglionic efferent neurons localized in the brainstem and spinal cord, whose axons innervate autonomic ganglia, sympathetic and parasympathetic, and modulate the enteric nervous system,
(ii) autonomic nuclei, with graded complexity, related to control and to pattern generation, localized in the hypothalamus and brainstem, besides the amygdala, thalamus, striatum, and cerebellum, and (iii) selected cortical areas.

These central autonomic regions are widely interconnected and constitute a complex network, with tonic, reflex and adaptive control over autonomic functions. Additionally, it regulates endocrine, behavioral, and other responses. The central ANS maintains continuity with the peripheral autonomic structures through which a delicate control is exerted on autonomic effectors of the viscera. Activity within the central ANS is state-dependent and affected by internal and external influences.15,16

The highly integrated patterns of autonomic functions are mostly generated in core structures including the hypothalamus (proposed as the main integrator by pioneer researchers) and the brainstem. The autonomic activities, as well as the endocrine and behavioral components of a given response, are exerted in a temporal and spatial sequence. A combination of responses of a more limited pattern with higher levels of organization results in the necessary adjustments of autonomic control. The hypothalamus may determine the overall characteristics of the response (and how it will fit with ongoing needs), whereas subsidiary pattern generators may each produce a series of response patterns, with graded complexities. The more complex generators exert control on more elementary autonomic (and endocrine, and motor) actions. When engaged in different combinations, these organized generators can produce the entire range of highly differentiated responses necessary to maintain homeostasis and other vital functions. The different pattern generators at varied levels of the neuraxis are organized in a hierarchical manner, so that they allow for individual response patterns to become part of larger responses, where the resultant action is arises from multiple level integration of autonomic pattern generators.2,15

Central autonomic structures and their interrelationships

The central autonomic regions include cortical areas, subcortical regions, brainstem, and spinal cord structures. Evidence obtained from neuroanatomical, lesional, electrophysiological, and functional studies indicate the role of several cortical areas in central autonomic modulation, including medial posterior frontal and posterior orbitofrontal areas, anterior cingulate area and insular cortex. These areas are the only known sources of projections from the cortex directly to subcortical autonomic centers, such as the hypothalamus and brainstem, and in addition, are reciprocally connected with limbic-paralimbic and heteromodal association areas.2,16-21

The subcortical autonomic centers are integrative regions where pattern generators of varied complexity are located, mainly in the hypothalamus and brainstem.15 The hypothalamus is a key regulatory center for autonomic and endocrine-metabolic control, and links the highest with the lowest levels of the neuroaxis.24-26 The brainstem is one of the most important regions regarding autonomic vital functions as it incorporates the respiratory, cardiovascular, and gastrointestinal control centers, represented by numerous nuclei (higher order processing autonomic nuclei [control and pattern generation], including periaqueductal gray (PAG), reticular formation nuclei (RF), nucleus tractus solitarius (NTS), parabrachial (PB) nuclear complex and dorsal motor vagal nucleus (DNV). The parasympathetic preganglionic neurons, including the pupillary (Edinger-Wetphal), salivatory (superior and inferior), and the DNV are also located here.27-30 Other subcortical structures of variable complexity, also play a role in autonomic integration, including the amygdala26,31-32 limbic and midline thalamic nuclei,33-36 accumbens,37 and the cerebellum, considering the cerebellar cortical-deep nuclei modules of the median region as a unit.38-41 All subcortical autonomic-related structures are widely interconnected, and relay cephalad projections to the cerebral cortex, and caudal projections to the spinal cord. In the spinal cord the preganglionic neurons are localized at the thoracolumbar [sympathetic] and sacral [parasympathetic] levels. The preganglionic neurons of the brainstem and spinal cord innervate the parasympathetic and sympathetic autonomic ganglia and the enteric nervous system which are directly related to cephalic, thoracic, abdominal and pelvic autonomic effectors.42-46 These regions participate in the constitution of complex neural networks linking high-level cognitive and affective sites with lower integrating structures to influence autonomic, emotional and behavioral responses.15

The neurodegeneration of central autonomic-related structures in Alzheimer’s disease

The main neuropathological markers of AD have been known for more than a century.37-40 They include senile plaques (SPs) and neurofibrillary tangles (NFTs), in varied stages of development. These changes follow a characteristic sequence, where, at the cortical level, the hippocampal formation is the earliest affected structure, followed progressively by other allocortical and finally, neocortical areas.26,33 Besides the well studied cortical areas there are the less studied subcortical structures that may be equally affected by the neurodegeneration, but for which less information is available.

The basic markers, namely neurofibrillary degeneration (NFTs, including neuropil threads, and components of
neuritic plaques) and SPs (seen in varied stages of formation, presenting dystrophic neurites in mature SPs – the neuritic plaques) characteristic of this neurodegenerative process, are not seen homogeneously across the several neural levels. There can be a predominance of one of the other, according to the examined region. The distribution pattern of SPs is different to NFTs. SPs commonly present a patchy distribution and a varied density, even considering the architectonic limits of the several areas. The inconsistent presence, varied density and pattern of distribution of SPs preclude the use of this marker for reliable neuropathological staging of the disease. On the other hand, NFTs present a well-defined sequential pattern, permitting differentiation of stages, and show better correlation with severity of the disease. The high number of NFTs, not the volume of amyloid deposits, corresponds to the reduction of the number of neurons in all studied areas. This progressive neuronal loss, as well as interconnections, is accompanied by functional impairment expressed as clinical symptoms of the disease. These long-known markers, revealed by the classic staining techniques (aniline, silver) still in use today, are visible on optical microscopy. Recently, numerous techniques have been developed which are now used in addition to the classical techniques to verify neuropathological aspects linked to the neurodegenerative process. The newer staining techniques, including immunological variants, allow earlier and more detailed visualization of the pathological material (thioflavine S and anti-beta/A4 [for amyloid], mab tau-1, mab-Alz50, AT8 and anti-PHF serum 60e, mab 3-39 to PHF [for tau and abnormally phosphorylated tau], mab 3-39 to PHF, which recognizes the carboxy terminal domain of ubiquitin). The immunocytochemical methods (such as AT8) permit assessment of neuronal changes antedating the formation of NFTs, and follow, in the same way, the sequence and stages previously established with the classic techniques.

The information that follows takes into account the presence of neurodegeneration of the affected structures irrespective of the techniques employed to show the pathological changes, unless they are necessary for a better understanding. Morphometric is included whenever available and the specific pathological changes in the described structures will be related to the neurofibrillary degenerative Braak and Braak’s stages, whenever available. This staging is accepted and used by most authors as the best pathological staging system and a time-line for the progression of the disease.

Cerebral cortex
The cortical areas are known to be affected by the neurodegeneration in a progressive and sequential manner, classified as I-II (transentorhinal), III-IV (limbic) and V-VI (isocortical) Braak and Braak stages. The changes first emerge in entorhinal areas (stage I-II), and progress to other limbic and paralimbic structures (the more severely affected), followed by heteromodal associative structures. The autonomic-related areas (prefrontal medial and orbitary), the anterior part of the cingulate gyrus, and the insular cortex become progressively involved from stage III-IV, reaching maximum severity at stage V-VI. The severity is higher than in any associative areas of the frontal, parietal and occipital lobes, and comparable to the involvement of the temporal cortex.

Subcortical structures
The autonomic-related subcortical structures include the amygdala, thalamus, basal ganglia, hypothalamus, and cerebellum.

Amygdala
Strong neurodegenerative changes are seen early in the disease (stage II-III), attaining the highest degree of neurofibrillary degeneration in the more advanced stages. The degeneration was seen in the cortical, mediobasal, lateral, basal accessory, lateral basal and central nuclei, but there is no consensus among authors about the intensity of lesions in the several nuclei, possibly due to the restricted number of cases in each study. Morphometric data also contribute toward evaluating the degree of the degenerative lesions. Such studies show that the amygdala and its subnuclei undergo severe volumetric atrophy. Total numbers of neurons were reduced significantly where medium and large neurons were predominantly affected. There is a neuron loss of about 50% in each amygdala. The subdivisions showed a differential neuron loss ranging from 35% in nucleus lateralis to 70% in the basalis.

Thalamus
Severe changes were confined to some of the limbic nuclei. The anterior (anterodorsal), dorsomedial, and laterodorsal nuclei showed changes early in the disease process (stage I-II), and reached heavy NFT burden from stage IV onwards. The anteroventral nucleus presents changes at stage IV and reaches maximum burden at stage VI. Among the midline nuclei, the paraventricular and reunions began NFTs load at stage IV and peaked at stage VI. Other nuclei were affected in later stages.

Basal ganglia
Neurofibrillary degeneration was present throughout the striatum, but displayed significantly higher densities in the ventral part (nucleus accumbens and olfactory tubercle). The changes began at stage III-IV and became more
severe at VI. The dorsal striatum was affected later, at stage V-VI. No neurodegeneration was found in the globus pallidus. These findings suggest that the 'limbic' striatum is particularly vulnerable to AD pathology.73-76

**Hypothalamus**

Several of its regions and nuclei are severely affected by the neurodegenerative process. The various nuclei are not involved simultaneously and show different staining patterns. The intensity also varied among the reports, probably due to different severity stages examined and different staining methods. The lateral hypothalamus (tuberomamillary, lateral tuberal, posterior) was affected from stage IV onwards and affected maximally at stage VI; supraoptic (supraoptic, paraventricular), followed in severity by the mediobasal hypothalamus (dorsomedial, ventromedial, tuberomammillary, lateral tuberal, tuberoinfundibular nuclei, tuberal grey, periventricular), and the anterior hypothalamus (sexually dimorphic and suprachiasmatic nuclei, periventricular area, arcuate, median eminence) was affected less intensely and only in later stages.10,61,70,77-81

**Cerebellum**

The cerebellum had long been a relatively neglected area of the AD brain, believed to be unaffected by specific neuropathology. A number of studies, although controversial, have revealed that pathological changes are present. Neurodegenerative changes have been observed, such as amyloid deposits (diffuse plaques, compact plaques), but NFTs were absent. The majority of plaques occur in the molecular layer, extending to the Purkinje cell layer and seldom into the granular layer.82-85 Morphometric data, in comparison to controls, provides some clarification. There was, in severe cases, a decrease in the volume of the molecular (24%) and granular (22%) layers. A reduction in the total number of Purkinje cells (32%) was seen to correlate with atrophy of the molecular layer. There was a similar reduction in the total number of granule cells (30%), which correlated with atrophy of the molecular and granular layers. Purkinje cell density, measured in the vermis and cerebellar hemispheres, showed the mean number of these cells to be significantly decreased in the vermis. Atrophy in the vermis was also more severe. The correlation between the temporal duration and both cortical neuronal and volumetric losses of the molecular and granular cortical layers indicate that these cerebellar atrophic changes most likely represent the disease process involving mainly the vermis.86,87

**Brainstem and spinal cord**

The neurodegenerative process affects the brainstem in a heterogeneous manner, displaying a decreasing rostral-caudal gradient while affecting more superior and dorsal regions and reaching the lowest degree in the most caudal segments, where it meets the spinal cord. The specific pathology is well expressed in these structures. Although there were no data on stage-related changes, the duration of dementia of the studied cases ranged between 2 and 17 years, possibly including all stages of the disease.

The majority of cranial nerve nuclei are generally spared. Only those that belong to the cranial autonomic parasympathetic outflow are clearly affected, including the pupillary nucleus (Edinger-Westphal) and the DNV, that give rise to parasympathetic preganglionic fibers, display a marked neuronal loss. Additionally, the NTS, an important afferent centre (for the VII, IX, X nerves) and relay station for several autonomic reflexes (cardiovascular, respiratory, gastrointestinal), besides the nucleus ambiguous that innervates muscles of branchial origin (IX, X, XI nerves), are also affected.57,88,89

The aminergic mesencephalic (dopaminergic of the substantia nigra compacta and ventral tegmental area), pontomesencephalic (serotonergic, cholinergic, noradrenergic nuclei), and medullary (adrenergic) are clearly affected.57,77,90,91

Several nuclei of the RF are affected in the mesencephalon, pons (tegmentopontine, oral and caudal), and medulla (medial and lateral). They are related to several mechanisms, including cardiovascular and respiratory control, swallowing, defecation and urination.57,88,92-95

The more complex autonomic centers such as the PAG, pontine PB complex, and intermediate reticular zone (IRZ) of the medulla, show neurodegenerative lesions of variable intensity. The nuclei of the PB complex together with the IRZ are pivotal relay stations within central autonomic regulatory feedback systems. The nuclei of the PB region and the IRZ display specific pathology at stage I-II that corresponds to the preclinical phase of AD. In stage III-IV (mild AD) these nuclei are already severely affected. In stage V-VI (moderate and severe AD), PB nuclei are filled with abnormal intraneuronal material, and the IRZ shows severe damage. The state of the AD-related neurodegeneration of the nuclei of the PB and the IRZ conforms to the cortical neurofibrillary I-VI staging.88,96

The spinal cord in AD was seldom studied. There are a few reports, mainly from the older literature, generally without mentioning specific pathology (in AD cases) or with scant or inconsistent findings occurring in most advanced stages of the disease. A very small number of tangles were found infrequently in the central region and intermediolateral column (origin of sympathetic preganglionic fibers), and occasionally in the dorsal and ventral gray in a small proportion of cases (‘senile dementia’).
The presence of fatty degeneration and pigmentary accumulation (lipofuscin) in the smaller and larger neurons of the anterior horn, with non-specific fibrillar changes was also described. Thus, neurodegenerative changes were considered to be absent in the spinal cord. More recent papers have focused on the spinal cord. One of these reports that the spinal cord exhibits little or no pathological changes in AD. Another study, which investigated tau-related pathology, detected tau immunoreactivity in neurons of the anterior horn (some with NFTs), but less frequently seen in the intermediate zone and posterior horn. Other regions (intermediolateral column and Onuf’s nucleus) showed no tau pathology. These abnormal cytoskeletal changes were more consistently observed in the cervical enlargement, followed by the thoracic cord and to a lesser extent in the lumbar enlargement. Finally, one paper described pathological tau in the spinal cord, in addition to less frequently seen neurofibrillary lesions. These lesions were most frequently found in the substantia intermedia, and also occurred in the lateral and dorsal horns, as well as in the ventral horns (more often in small neurons and less frequently in anterior horn cells). The autonomic nervous system, in its normal state governs visceral functions, and its activity is expressed in relation to homeostatic needs of the organism considering its current physical and mental activities. However, if these functions and their compensatory mechanisms begin to fail, autonomic dysfunction or dysautonomy ensues.

Concluding remarks
Alzheimer’s disease is a multi-faceted disorder best known for its cognitive, behavioral and motor dysfunctions. Despite its importance, autonomic impairment has received far less attention. The normal anatomy, connections, and function of the central autonomic-related structures have been reasonably well studied. They constitute neural networks of varied complexity and with a hierarchical nature that underpin vital functions. These structures span from the cerebral cortex to the spinal cord, and include several important subcortical structures (amygdala, thalamus, hypothalamus, brainstem, cerebellum).

However, the neurodegenerative pathology of these autonomic-related structures have not been studied with the same intensity as the cerebral cortex, and only isolated studies partially describing this important issue were found. The present review pools practically all studies found on the central autonomic-related structures affected by specific Alzheimer’s disease neurodegeneration together and describes them in a detailed and systematic way. The present description of these less studied neuropathologically affected regions followed the same sequence used for the relatively well-known structures and their networks in normal states so as to facilitate (dys) functional understanding. All encephalic levels, with the spinal cord practically spared, are affected by the neurodegenerative process to varying degrees, from mild to severe. There seems to be a sequential progression that parallels the Braak and Braak stages, but this was not always revealed in view of the limited data available.

The neurodegenerative changes impair function and lead to death of the involved neurons. Consequently, the autonomic mechanisms progressively deteriorate commensurate with the advancing cortical neurofibrillar stages, causing autonomic dysfunction. The affected neural networks, when damaged by the progressive neurodegeneration, fail to maintain their specific vital activities. Thus they represent the neuropathological substrate of autonomic dysfunction.

This dysautonomy may be expressed through clinical manifestations in the autonomic range which may appear from the beginning of the clinical phase of the disease and progress to more severe phases. The knowledge that a dysautonomic state perpetuates throughout the course of the disease is pivotal for its recognition (clinical or subclinical), and for the introduction of possible corrective measures. The appearance of adverse events upon use of therapeutic agents can also be correctly interpreted. The presence of this dysfunction and its possible link to higher morbidity, and perhaps mortality, in affected subjects must be kept in mind when managing Alzheimer patients.

Therefore, in parallel to well established knowledge of the cognitive, behavioral, psychological, and motor manifestations, it seems paramount to dedicate similar attention to the autonomic dysfunction of Alzheimer’s disease.

Acknowledgements – The authors thank Luzinete N.O. Alvarenga for her editorial assistance.

References
1. Coote JH. Respiratory and circulatory control during sleep. J Exp Biol 1982;100:223-244.
2. Engelhardt E, Esbérard CA. The dysautonomy in Alzheimer’s disease. Rev Bras Neurol 2005;41:31-42.
3. Silverthorn DU. Fisiologia Humana. Uma Abordagem Integrada. 2º. ed. São Paulo: Manole; 2003.
4. Herd JA. The physiology of strong emotions: Cannon’s Scientific Legacy Re-examined. Physiologist 1972;15:5-16.
5. Chu CC, Tranel D, Damasio AR, van Hoesen GV. The autonomic-related cortex: pathology in Alzheimer’s disease. Cereb Cortex 1997;7:86-95.
6. Dampney RAL, Coleman MJ, Fontes MAP, et al. Central Mechanisms Underlying Short- and Long-Term Regulation
of the Cardiovascular System. Clin Exp Pharmacol Physiol 2002;29:261-268.
7. McDougall SJ, Widdop RE, Lawrence AJ. Central autonomic integration of psychological stressors: Focus on cardiovascular modulation. Autonom Neurosci (in press).
8. Patton HD. The Autonomic Nervous System. In: Patton HD, Fuchs AF, Hille B, Scher AM, Steiner R, Editors. Textbook of Physiology. 21st Edition, vol. I. Philadelphia: WB Saunders; 1989:737-758.
9. Sachs W. The vegetative nervous system. A clinical study. London: Cassel and Company Ltd;1936.
10. Saper CB, German DC. Hypothalamic pathology in Alzheimer’s disease. Neurosci Lett 1987;74:364-370.
11. Allan LM, Ballard CG, Allen J, et al. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry 2007;78:671-677.
12. Kaufmann H, Biaggioni I. Autonomic failure in neurodegenerative disorders. Semin Neurosci 2003;23:351-363.
13. Mathias CJ. Autonomic diseases: clinical features and laboratory evaluation. J Neurol Neurosurg Psychiatry 2003;74(suppl. III):31-41.
14. Royall DR, Gao JH, Kellogg DL Jr. Insular Alzheimer’s disease pathology as a cause of “age-related” autonomic dysfunction and mortality in the non-demented elderly. Med Hypotheses 2006;67:747-758.
15. Saper CB. The Central autonomic nervous system: conscious visceral perception and autonomic pattern generation. Ann Rev Neurosci 2002;25:433-469.
16. Wong SW, Massé N, Kimmerly DS, et al. Ventral medial prefrontal cortex and cardiovagal control in conscious humans. Neuroimage 2007;35:698-708.
17. An X, Bandler R, Ongur D, Price JL. Prefrontal cortical projections to longitudinal columns in the midbrain periaqueductal gray in macaque monkeys. J Comp Neurol 1998;401:455-479.
18. Critchley HD, Mathias CJ, Josephs O, et al. Human cingulate cortex and autonomic control: converging neuroimaging and clinical evidence. Brain 2003;126:2139.
19. Critchley HD. Neural mechanisms of autonomic, affective, and cognitive integration. J Comp Neurol 2005;493:154-166.
20. van Hoesen GW, Parvizi J, Chu CC. Orbitofrontal cortex pathology in Alzheimer’s disease. Cereb Cortex 2000;10:243-251.
21. Meyer S, Strittmatter M, Fischer C, Georg T, Schmitz B. Lateraalphization in autonomic dysfunction in ischemic stroke involving the insular cortex. Neuropeport 2004;15:357-361.
22. Oppenheimer SM. Neurogenic cardiac effects of cerebrovascular disease. Curr Opin Neurol 1994;7:20-24.
23. Oppenheimer S. Cerebrogenic cardiac arrhythmias: cortical lateralization and clinical significance. Clin Auton Res 2006;16:66-11.
24. Martin JH. Neuroanatomy, 2nd Ed. Stamford: Appleton & Lange;1996.
25. Pelosi GG, Tavares RF, Correa FM. Rostrocaudal somatotopy in the neural connections between the lateral hypothalamus and the dorsal periaqueductal gray of the rat brain. Cell Mol Neurobiol 2006;26:635-43.
26. Rempel-Clower NL, Barbas H. Topographic organization of connections between the hypothalamus and prefrontal cortex in the rhesus monkey. J Comp Neurol 1998;398:393-419.
27. Aicher SA, Reis DJ, Nicola R, Milner TA. Monosynaptic projections from the medullary gigantocellular reticular formation to sympathetic preganglionic neurons in the thoracic spinal cord. J Comp Neurol 1995;363:563-580.
28. Andresen MC, Doyle MW, Bailey TW, et al. Differentiation of autonomic reflex control begins with cellular mechanisms at the first synapse within the nucleus tractus solitarius. Braz J Med Biol Res 2004;37:549-558.
29. Hayward LF, Castellanos M, Davenport PW. Parabrachial neurones mediate dorsal periaqueductal gray evoked respiratory responses in the rat. J Appl Physiol 2004;96:1146-1154.
30. Zhang W, Hayward LF, Davenport PW. Respiratory responses elicited by rostral versus caudal dorsal periaqueductal gray stimulation in rats. Auton Neurosci 2007;134:45-54.
31. LeDoux JE. Emotion circuitry in the brain. Ann Rev Neurosci 2000;23:155-184.
32. Saha S. Role of the central nucleus of the amygdala in the control of blood pressure: ascending pathways to medullary cardiovascular nuclei. Clin Exp Pharmacol Physiol 2005;32:450-456.
33. Huang H, Ghosh P, van den Pol AN. Prefrontal cortex-projecting glutamatergic thalamic paraventricular nucleus-excited by hypocretin: a feedforward circuit that may enhance cognitive arousal. J Neurophysiol 2006;95:1656-1668.
34. Krouth KE, Belzer RE, Loewy AD. Brainstem projections to midline and intralaminar thalamic nuclei of the rat. J Comp Neurol 2002;448:53-101.
35. Otake K, Nakamura Y. Single midline thalamic neurones projecting to both the ventral striatum and the prefrontal cortex in the rat. Neuroscience 1998;86:635-649.
36. Taber KH, Wen C, Khan A, Hurley RA. The limbic thalamus. J Neuropsychiatry Clin Neurosci 2004;16:127-132.
37. Giménez-Amaya JM, McFarland NR, de las Heras S, et al. Organization of thalamic projections to the ventral striatum in the primate. J Comp Neurol 1995;354:127-149.
38. Giuditta M, Ruggiero DA, Del Bo A. Anatomical basis for the fastigial pressor response. Blood Press 2003;12:175-180.
39. Haines DE, Dietrichs E, Mihailoff GA, McDonald EF. The cerebellar-hypothalamic axis: basic circuits and clinical observations. Int Rev Neurobiol 1997;41:83.
40. Onat F, Cavdar S. Cerebellar connections: hypothalamic. Cerebellum 2003;2:263-269.
41. Wen YQ, Zhu JN, Zhang YP, Wang JJ. Cerebellar interpositus nuclear inputs impinge on paraventricular neurons of the hypothalamus in rats. Neuroscience Letters, 2004;370:25-29.
42. Zhu JN, Yung WH, Kwok-Chong Chow B, et al. The cerebel-
lar-hypothalamic circuits: potential pathways underlying cerebellar involvement in somatic-visceral integration. Brain Res Rev 2006;52:93-106.

43. Mouton LJ, Kerstens L, Van der Want J, Holstege G. Dorsal border periaqueductal gray neurons project to the area directly adjacent to the central canal ependyma of the C4-T8 spinal cord in the cat. Exp Brain Res 1996;112:11-23.

44. Mtui EP, Anwar M, Gomez R, Reis DJ, Ruggiero DA. Projections from the nucleus tractus solitarius to the spinal cord. J Comp Neurol 1993;337:231-252.

45. Pyner S and Coote JH. Identification of branching paraventricular neurons of the hypothalamus that project to the rostroventrolateral medulla and spinal cord. Neuroscience 2000;100:549-556.

46. Watanabe S, Kitamura T, Watanabe L, Sato H, Yamada J. Projections from the nucleus reticularis magnocellularis to the rat cervical cord using electrical stimulation and iontophoretic injection methods. Anat Sci Int 2003;78:42-52.

47. Alzheimer A. Uber eigenartige Krankheitsfälle des spätere Alters. Z gesamt Neurolog Psychiatr 1911;4:356-385.

48. Perusini G. Uber klinisch und histologisch eigenartige psychische erkrankung des spätere Lebensalters. Histol Histopathol Arb Grosshirnrinde 1909;3:297-358.

49. Simchowicz T. Histologische Studien über die senile Demenz. Histol u Histopathol Arb Grosshirnrinde 1909;3:297-358.

50. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991a;82:239-259.

51. Delacourte A, David JP, Sergeant N, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. Neurology 1999;52:1158-1165.

52. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992;42:631-639.

53. Rüb U, Del Tredici K, Del Turco D, Braak H. The intralaminar nuclei assigned to the medial pain system and other components of this system are early and progressively affected by the Alzheimer’s disease-related cytoskeletal pathology. J Chem Neuroanat 2002;23:279-290.

54. Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 1995;16:271-278.

55. Giess R, Schlote W. Localisation and association of pathomorphological changes at brainstem in Alzheimer’s disease. Mech Ageing Development 1995;84:209-226.

56. Nagy Z, Esiri MM, Jobst KA, et al. Relative roles of plaques and tangles in the dementia of Alzheimer’s disease: correlations using three sets of neuropathological criteria. Dementia 1995;6:21-31.

57. Parvizi J, Van Hoesen GW, Damasio A. The selective vulnerability of brainstem nuclei to Alzheimer’s disease. Ann Neurol 2001;49:53-66.

58. Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 2004;62:1984-1989.

59. Giannakopoulos P, Herrmann FR, Bussière T, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology 2003;60:1495-1500.

60. Bontius DJ, Solodkin A, van Hoesen GW. Pathology of the Insular Cortex in Alzheimer Disease Depends on Cortical Architecture. J Neuropathol Exp Neurol 2005;64:910-922.

61. Swaab DF, Grundke-Iqbal I, Iqbal K, et al. Tau and ubiquitin in the human hypothalamus in aging and Alzheimer’s disease. Brain Res 1992;590:239-249.

62. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex 1991;1:103-116.

63. Kromer Vogt LJ, Hyman BT, Van Hoesen GW, Damasio AR. Pathological alterations in the amygdala in Alzheimer’s disease. Neuroscience 1990;37:377-385.

64. Unger JW, Lapham IW, McNeill TH, et al. The amygdala in Alzheimer’s disease: neuropathology and Alz 50 immunoreactivity. Neurobiol Aging 1991;12:389-399.

65. Yilmazer-Hanke DM. Alzheimer’s disease. The density of amygdalar neuritic plaques is associated with the severity of neurofibrillary pathology and the degree of beta-amyloid protein deposition in the cerebral cortex. Acta Anat (Basel) 1998;162:46-55.

66. Scott SA, DeKosky ST, Sparks DL, Knox CA, Scheff SW. Amygdala cell loss and atrophy in Alzheimer’s disease. Ann Neurol 1992;32:555-563.

67. Vereeken TH, Vogels OJ, Nieuwenhuys R. Neuron loss and shrinkage in the amygdala in Alzheimer’s disease. Neurobiol Aging 1994;15:45-54.

68. Braak H, Braak E. Alzheimer’s disease affects limbic nuclei of the thalamus. Acta Neuropathol 1991;81:261-268.

69. Grossi D, Lopez OL, Martinez AJ. Mamillary bodies in alzheimer’s disease. Acta Neurol Scand 1989;80:41-45.

70. McDuff T, Sumi SM. Subcortical degeneration in Alzheimer’s disease. Neurology 1985;35:123-126.

71. Paskavitz JF, Lippa CF, Hamos JE, et al. Role of the dorsomedial nucleus of the thalamus in Alzheimer’s disease. J Geriatr Psychiatry Neurol 1995;8:32-37.

72. van der Werf YD, Witter MP, Groenewegen HJ. The intralaminar and midline nuclei of the thalamus. Anatomical and functional evidence for participation in processes of arousal and awareness. Brain Res Brain Res Rev 2002;39:107-140.

73. Braak H, Braak E. Alzheimer’s disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol 1990;49:215-224.

74. Brilliant MJ, Elble RJ, Ghobrial M, Struble RG. The distribution of amyloid beta protein deposition in the corpus stria-
75. Selden N, Mesulam MM, Geula C. Human striatum: the distribution of neurofibrillary tangles in Alzheimer’s disease. Brain Res 1994a;648:327-331.
76. Selden N, Geula C, Hersh L, Mesulam MM. Human striatum: chemoarchitecture of the caudate nucleus, putamen and ventral striatum in health and Alzheimer’s disease. Neuroscience 1994b;60:621-636.
77. Burke WJ, Coronado PG, Schmitt CA, et al. Blood pressure regulation in Alzheimer’s disease. J Auton Nerv Syst 1994b;48:65-71.
78. Byrne W, Mattiace L, Kress Y, Davies P. Alz-50 immunoreactivity in the hypothalamus of the normal and Alzheimer human and the rat. J Comp Neurol 1991;306:602-612.
79. Nakamura S, Takemura M, Ohnishi K, et al. Loss of large neurons and occurrence of neurofibrillary tangles in the tuberomammillary nucleus of patients with Alzheimer’s disease. Neurosci Lett 1993;151:196-199.
80. van de Nes JA, Kamphorst W, Ravid R, Swaab DF. The distribution of Alz-50 immunoreactivity in the hypothalamus and adjoining areas of Alzheimer’s disease patients. Brain 1993;116:103-115.
81. Schultz C, Ghebremedhin E, Braak H, Braak E. Neurofibrillary pathology in the human paraventricular and supraoptic nuclei. Acta Neuropathol 1997;94:99-102.
82. Larner AJ. The cerebellum in Alzheimer’s disease. Dement Geriatr Cogn Disord 1997;8:203-209.
83. Braak H, Braak E, Bohl J, Lang W. Alzheimer’s disease: amyloid plaques in the cerebellum. J Neurol Sci 1989;93:277-287.
84. Suenaga T, Hirano A, Llena JF, et al. Modified Bielschowsky and immunocytochemical studies on cerebellar plaques in Alzheimer’s disease. J Neuropath Exp Neurol 1990;49:31-40.
85. Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer’s disease. Am J Pathol 1989;135:309-319.
86. Wegiel J, Wisniewska HM, Dziewiatkowskib J, et al. Cerebellar atrophy in Alzheimer’s disease-clinico pathological correlations. Brain Res 1999;818:41-50.
87. Sjöbeck M, Englund E. Alzheimer’s disease and the cerebelum: a morphologic study on neuronal and glial changes. Dement Geriatr Cogn Dis 2001;12:211-218.
88. Rüb U, Schultz C, Tredici K, Braak H. Early involvement of tegmentopontine reticular nucleus during the evolution of Alzheimer’s disease-related cytoskeletal pathology. Brain Res 2001a;908:107-112.
89. Scinto LF, Frosch M, Wu CK, Daffner KR, Gedi N, Geula C. Selective cell loss in Edinger-Westphal in asymptomatic elders and Alzheimer’s patients. Neurobiol Aging 2001;22:729-736.
90. Marcyniuk B, Mann DM e Yates PO. The topography of cell loss from locus coeruleus in Alzheimer’s disease. J Neurol Sci 1986;76:335-345.
91. Zweig RM, Ross CA, Hedreen JC et al. Neuropathology of aminergic nuclei in Alzheimer’s disease. Prog Clin Biol Res 1989;317:353-365.
92. Iseki E, Matsushita M, Kosaka K et al. Distribution and morphology of brain stem plaques in Alzheimer’s disease. Acta Neuropathol 1989;78:131-136.
93. Kemper TL. Neuroanatomical and Neuropathological Changes During Aging and Dementia. In: Albert ML e Knoefel JE, editors. Clinical neurology of aging. 2nd Ed. Oxford: Oxford University Press;1994:3-67.
94. Mosqueda-Garcia R. Central autonomic regulation. In: Robertson D, Low PA, Polinsky RJ, editors. Primer on the autonomic nervous system. San Diego: Academic Press;1996:3-12.
95. Rüb U, Tredici K, Schultz C, Thal DR et al. The autonomic higher order processing nuclei of the lower brain stem are among the early targets of the Alzheimer’s disease-related cytoskeletal pathology. Acta Neuropathol 2001b;101:555-564.
96. Parvizi J, van Hoesen GW, Damasio A. Selective pathological changes of the periaqueductal gray matter in Alzheimer’s disease. Ann Neurol 2000;48:344-353.
97. Bohl J, Ulbricht D, Steinmetz H. Neurofibrillary tangles in peripheral autonomic ganglion cells. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM, editors. Alzheimer’s disease: biology, diagnosis and therapeutics. Chichester: John Wiley & Sons Ltd;1997:281-287.
98. Saito Y, Murayama S. Expression of tau immunoreactivity in the spinal motor neurons of Alzheimer’s disease. Neurology 2000;55:1727-1730.
99. Schmidt ML, Zhukareva V, Perl DP et al. Spinal cord neurofibrillary pathology in Alzheimer disease and guam Parkinsonism-dementia complex. J Neuropathol Exp Neurol 2001;60:1075-1086.
100. Yamada M. On the distribution of senile changes in the spinal cord. Folia Psychiatr Neurol Jpn 1978;32:249-251.